LRATD1

Across TCGA pan-cancer cohorts, LRATD1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of LRATD1’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where LRATD1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types LRATD1 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

LSCC, HNSC, and CCRCC are the cancer types where LRATD1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LRATD1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	+0.582	<.001	7	view →
HNSC	Male	All	−0.356	.002	6	view →
CCRCC	All	All	+0.608	<.001	5	view →
COAD	Male	III,IV	−0.305	.024	4	view →
LUAD	All	All	−0.514	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

LRATD1–LSCC

Open the LSCC breakdown →